Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0699790 (colon cancer)
 28,837 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A patient is described with colon cancer and liver metastases who developed a bronchobiliary fistula 2 years after hepatic resection. The diagnostic approach and clinical management are presented and the literature is reviewed.
 ...
PMID:Bronchobiliary fistula after hepatic resection for metastatic colon cancer. 670 Feb 33

A Phase I trial of tricyclic nucleoside phosphate (1,4,5,6,8-pentaazaacenaphthylene-3-amino-1, 5-dihydro-5-methyl-1-beta-D-ribofuranosyl 5'-phosphate ester; NSC 280594) was conducted using a 5-day continuous infusion schedule. Thirty-seven patients with advanced cancer were entered on the study, of whom 33 patients were evaluable for response and toxicity. Dose levels ranged from 10 mg/sq m/day X 5 days to 40 mg/sq m/day X 5 days. Initially, courses were repeated every 3 to 4 weeks. As cumulative toxicity became manifested, the interval between courses was changed to every 6 weeks. Major toxicities included hyperglycemia, hepatotoxicity, and thrombocytopenia. Patients with a prior history of diabetes mellitus, extensive radiation therapy, or significant liver metastases were prone to severe toxicity. Other toxicities noted were nausea and vomiting, abdominal discomfort, anemia, and reduction in serum calcium, phosphorus, and albumin levels. Rare side effects included hypertriglyceridemia, hyperamylasemia, diarrhea, and stomatitis. Antitumor activity observed include improvement in s.c. metastases in a patient with papillary thyroid carcinoma, stabilization of disease in a patient with mesothelioma, and mixed responses in three patients (colon cancer, sarcoma, and tonsillar squamous cell cancer). Recommended schedule for Phase II studies is 20 mg/sq m/day for 5 days every 6 weeks.
 ...
PMID:Phase I study of tricyclic nucleoside phosphate using a five-day continuous infusion schedule. 674 83

Urine samples collected from patients with colon carcinoma and from normal donors were tested for antigenic activity by the microcomplement-fixation assay. When autologous serum was used as the antibody source, 65.4% (17/26) of the urine samples from patients with colon carcinoma were positive for antigen as opposed to only 10% (2/20) from normal volunteers. Absorption of a representative serum with cultured colon cancer cells completely removed reactivity against its autologous urine. Using this serum to screen urine from colon carcinoma patients, antigenic activity was found in 71.4% (30/46) of the samples; however, only 10% (2/20) of the urine samples from apparently healthy volunteers were positive. Analysis of urine samples collected from three patients before and after resection of their primary colon carcinoma and from nine patients undergoing hyperthermia for liver metastases revealed that two of the patients who had curative surgical procedures had marked decreases in urinary antigen levels by the second postoperative day, while the third patient whose disease was unresectable had no significant decrease. Seven of nine patients with metastatic disease had a greater than fourfold increase in antigen activity after hyperthermia and chemotherapy. These results suggest that tumor-associated antigens were excreted into urine, possibly the result of treatment-caused tumor necrosis. Therefore, assessment of tumor-associated antigen(s) in the urine of patients with colon carcinoma may serve as a marker for response to treatment of this disease.
 ...
PMID:Excretion of tumor-associated antigen(s) in the urine of patients with colon carcinoma. 713 64

Glycoprotein antigens were extracted with perchloric acid (PCA) from the 14 individual lung anaplastic cancers and 4 lung adenocarcinomas and their antigenic activity was compared with carcinoembryonic antigen (CEA) isolated from liver metastases of colon cancer. The studies were performed by double immunodiffusion, immunoelectrophoresis and radioimmunoassay, using the specific immune sera against PCA-extracted glycoproteins of lung anaplastic cancer (anti-80 PCA-CaLu), and also anti-CEA, anti-AFP, and anti-alpha 1-acid glycoprotein sera. The existence of at least three groups of antigens in lung cancers was demonstrated, i. e. CEA-like antigen, group antigen characteristic for most of the lung anaplastic cancers and lung adenocarcinomas non-related to CEA and antigen(s) detectable only in some of anaplastic cancers. Moreover antigen of alpha 1-acid glycoprotein reactivity was detected in all lung cancers studied.
 ...
PMID:Immunological reactivity of glycoprotein antigens from human lung cancers. 725 22

Angiogenesis inhibitors have attracted considerable interest. The anti-tumor and anti-metastatic effects of TNP-470, an angiogenesis inhibitor, and mitomycin C (MMC), a representative anti-neoplastic agent, were investigated using a xenotransplanted human colon cancer, TK-4. Suturing of small pieces of TK-4 tumors to the cecal wall in nude mice (orthotopic transplantation) induced liver metastasis. Mice were randomly divided into 3 groups; a control group given saline solution, a group receiving TNP-470 and a group receiving MMC. TNP-470 was given s.c. on alternate days for 5 weeks from day 10 after cecal transplantation and MMC was administered intraperitoneally (i.p.) once a week from day 10 after cecal transplantation. MMC significantly inhibited cecal tumor growth. In the control group, liver metastases developed in 9 out of 10 mice, including 3 with more than 20 metastatic foci. Liver metastasis also developed in 8 out of 10 mice receiving MMC, 2 of which had many metastases. In contrast, liver metastasis developed in only 2 out of 8 mice in the TNP-470 group and neither of these animals had numerous metastases.
 ...
PMID:Comparison of the inhibitory effect of the angiogenesis inhibitor, TNP-470, and mitomycin C on the growth and liver metastasis of human colon cancer. 753 57

This study investigated the inhibitory effect of human macrophage colony stimulating factor (hM-CSF) on experimental liver metastases. Murine colon cancer cell lines C-26 and C-36 were each injected into the spleen of BALB/c mice and the number of subsequent liver metastases was counted. An optimal dose (3,000U/body/day) of hM-CSF to inhibit liver metastases was identified. Additionally, hM-CSF (3,000U/body/day) administration for 7 days before and after the injection of the same cancer cell lines was investigated. The mean number of liver metastases decreased significantly in the hM-CSF group compared with the saline group. These results suggest potential therapeutic benefit for the use of hM-CSF in the adjuvant treatment of liver metastases.
 ...
PMID:Macrophage colony stimulating factor inhibits experimental liver metastases from colon cancer. 754 64

A rabbit VX2 colon cancer model with spontaneous liver metastases was used to evaluate the antitumor effect of an angiogenesis inhibitor, FR-118487. FR-118487 (1 mg/kg/day) was infused continuously into the portal vein for a week after resection of primary colon cancer lesions (FR group). The incidence of liver metastases was 71.4% (5/7) in FR group, and 100% (7/7) in control group. The number and the weight of liver metastatic nodules were 31.0 +/0 36.0 and 1.4 +/- 1.8 g in FR group versus 83.7 +/- 73.9 and 6.5 +/- 4.9 g in control group, respectively. The metastases in FR group were significantly decreased in weight compared with those in control group (p < 0.05). No anastomotic leakage was recognized in either group. No side effects of FR-118487 such as body weight loss were found. Continuous intraportal infusion of FR-118487 in the early postoperative period may be effective to suppress liver metastases from colon cancer by inhibiting the angiogenesis concerning liver metastases.
 ...
PMID:[Suppression of postoperative liver metastases from colon cancer by continuous intraportal infusion of an angiogenesis inhibitor FR-118487]. 757 37

Chronochemotherapy was performed in two cases of metastatic liver cancer. One was a 51-year-old woman whose pancreas tumor was incompletely removed six months ago and had a residual pancreas tumor (30 x 20 mm2) with liver metastases in S4. Another was a 54-year-old woman whose sigma colon cancer had been removed 10 months ago. A large metastatic tumor in the fourth section of the liver and multiple daughter tumors in other parts of the liver were seen. The hyperthermic chemotherapy using warmed 5% glucose solution administered intraarterially could not be used for these patients. The variable rate of infusion of 5FU (250 mg/body) and CDDP (3.3 mg/body) (23:19:00-7:00) (1/3:7:00-10:00) as chronotherapy showed more efficacy as an anti-cancer treatment compared to their continuous infusion.
 ...
PMID:[Chronochemotherapy in two cases of metastatic liver cancer]. 757 96

Pancreas cancer-associated antigen (PCAA), primarily isolated from the ascites of pancreatic cancer (PC) patients, is strongly positive in PC, colon cancer and normal colonic mucosa. In immunohistochemical staining of tumor tissues with antibodies, medullary thyroid carcinoma (MTC) was no less strongly positive for PCAA than PC, and we studied its details. Antibodies to PCAA, calcitonin and CEA were used in the immunostaining of normal thyroid tissues and thyroid tissues from patients with adenomas, MTC, papillary carcinomas, and follicular carcinomas. The PCAA from the liver metastases of MTC was studied for molecular weight and antigenicity in comparison with the PCAA from the ascites of PC patients. Serum levels of PCAA were determined in MTC patients. Of 11 patients with MTC, PCAA, calcitonin and CEA were studied immunohistologically and positive in 10, 11 and 10 patients, respectively. The PCAA from the metastases had a molecular weight of about 700,000, and was immunochemically identical to that from the ascites of PC patients. Serum levels of PCAA were elevated in 4 of 6 MTC patients. The thyroid tissues from the MTC patients, familial or non-familial, were as strongly positive for PCAA as for calcitonin and CEA. It was antigenically identical to that of PC origin, and positive in the serum of MTC patients.
 ...
PMID:Pancreas cancer-associated antigen (PCAA) in medullary thyroid carcinoma. 760 6

The c-src proto-oncogene has been implicated in the progression of primary human colorectal carcinoma to hepatic metastasis. To determine if increased pp60c-src tyrosine kinase activity is a colon-specific phenomenon present in colorectal metastases to all sites, the pp60c-src-specific kinase activity of noncolon tumor metastases to the liver was compared to that of colorectal liver metastases. Activity of extrahepatic colon carcinoma metastases was compared to that of colorectal liver metastases as well as that of normal colonic mucosa. The specific activity of pp60c-src in multiple synchronous metastases from colon carcinoma was also examined. Tyrosine kinase activity was determined by immune complex kinase assay; protein levels were determined by immunoblotting. Specific activity was calculated for each group by dividing the total activity by protein level. Colon carcinoma metastases to the liver had significantly (P < 0.04) increased pp60c-src activity with an average 2.2-fold increase over normal mucosa. In contrast, noncolon tumor metastases to the liver showed minimal pp60c-src kinase activity. Extrahepatic colorectal metastases demonstrated significantly increased (P < 0.005) pp60c-src activity with an average 12.7-fold increase over normal mucosa. When compared to colon liver metastases, extrahepatic colorectal tumor metastases show a significant difference in activity (P < 0.05) with an average 5.7-fold increase. Examination of multiple synchronous colon carcinoma metastases confirmed these results. In summary, we conclude that (1) the activation of pp60c-src between primary tumors and metastases is specific to colon metastases, and (2) although pp60c-src activity is significantly increased in colorectal metastases, site-specific differences in the magnitude of activity are evident.
 ...
PMID:Site-specific differences in pp60c-src activity in human colorectal metastases. 768 14


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>